 CAMBRIDGE, Mass.--BUSINESS WIRE--Alnylam Pharmaceuticals, Inc. Nasdaq: ALNY, the leading RNAi therapeutics company, announced today that the Company will present data from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated ATTR amyloidosis with cardiomyopathy, during a late-breaker session at the 18th International Symposium on Amyloidosis ISA on September 8, 2022. The Company announced positive topline 